The first-in-class XPO1 inhibitor selinexor has been approved for the treatment of relapsed and refractory multiple myeloma and diffuse large B cell lymphoma (DLBCL) and is currently under clinical evaluation in multiple solid and haematological malignancies. Here, XPO1 is linked to diffuse large B-cell lymphoma.